首頁 > 市場調查報告書 > 製藥

肥胖症

市場調查報告書

商品編碼

1918103

抗肥胖藥物市場－2026-2031年預測

Anti-Obesity Drug Market - Forecast from 2026 to 2031

出版日期: 2026年01月14日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計抗肥胖藥物市場將從 2025 年的 408.98 億美元成長到 2031 年的 1,163.81 億美元，維持 19.04% 的複合年成長率。

由於全球肥胖症及其相關健康問題日益嚴重，抗肥胖藥物市場預計將保持穩定成長。這些藥物透過抑制食慾和釋放兒茶酚胺等作用機制，為體重管理和維持永續健康提供了有醫學依據的途徑。人口結構、生活方式和監管因素的綜合影響推動了市場擴張，這些因素凸顯了有效治療方案的重要性。

市場的主要促進因素是全球各年齡層肥胖症盛行率的不斷上升，其中兒童肥胖症的驚人成長尤為突出。這一普遍存在的健康問題正顯著擴大需要醫療干預的患者群體。肥胖症與多種嚴重健康後果密切相關，進一步刺激了對肥胖藥物的需求。肥胖是多種慢性疾病的重要危險因素，包括第2型糖尿病和各種癌症，也是全球過早死亡的主要原因之一。肥胖與這些危及生命的合併症之間的直接關聯，有力地證明了抗肥胖藥物治療的必要性。

現代生活方式也是市場成長的關鍵促進因素。長時間久坐工作（尤其是在企業環境中）、加工食品的攝取、不規則的睡眠以及慢性壓力等因素，都造成了促進肥胖的環境。數位科技在日常生活中的普及化進一步加劇了這些久坐習慣。這些生活方式的集體改變已經形成了一個永續的肥胖人群群體，他們需要藥物輔助進行體重管理。

政府和機構的措施正在積極塑造市場格局。國際衛生組織和各國衛生署正在實施反肥胖宣傳宣傳活動和技術框架，並專注於預防，尤其是在兒童群體中。這些公共衛生措施透過教育大眾了解與體重相關的健康風險，並將肥胖定位為一種需要醫療干預的疾病，從而創造了有利於反肥胖治療的環境。

北美已成為重要的區域市場，這得益於其高肥胖率和完善的法規結構。該地區已獲得美國食品藥物管理局 (FDA)核准的多種長期體重管理藥物，為臨床醫生提供了豐富的治療選擇。大型製藥公司的存在，加上先進的技術基礎設施和大規模的研發活動，進一步鞏固了北美在抗肥胖治療領域藥物引進和創新方面的主導地位。

該市場蘊藏著巨大的成長機會，尤其是在開發療效和安全性更高的先進療法方面。全球因肥胖導致的大量死亡凸顯了開發更有效藥物干預措施的迫切性。然而，市場成長受到一些限制因素的限制，例如政府對藥物核准和使用的嚴格監管。其他挑戰包括體重管理服務的使用率低，以及基於體重指數（BMI）和合併症等因素限制某些患者群體獲得藥物的處方限制。

在競爭激烈的市場環境中，像 Currax Pharmaceuticals 和 GlaxoSmithKline 這樣的專業製藥公司銷售核准的產品，例如 Contrave® 和 Alli®。這些公司專注於個人化治療方案和宣傳宣傳活動，旨在解決肥胖的多種生理和行為問題，這反映了醫學界對肥胖的理解和治療方法日益成熟。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

介紹
北美洲
- 透過作用機制
- 按類型
- 透過行政途徑
- 最終用戶
- 按國家/地區
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 透過作用機制
- 按類型
- 透過行政途徑
- 最終用戶
- 按國家/地區
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 透過作用機制
- 按類型
- 透過行政途徑
- 最終用戶
- 按國家/地區
  - 德國
  - 法國
  - 英國
  - 西班牙
  - 其他
中東和非洲
- 透過作用機制
- 按類型
- 透過行政途徑
- 最終用戶
- 按國家/地區
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 以色列
  - 其他
亞太地區
- 透過作用機制
- 按類型
- 透過行政途徑
- 最終用戶
- 按國家/地區
  - 中國
  - 印度
  - 日本
  - 韓國
  - 印尼
  - 泰國
  - 台灣
  - 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
企業合併、協議、商業合作
競爭對手儀錶板

第11章公司簡介

Currax Pharmaceuticals LLC
GlaxoSmithKline PLC
Novo Nordisk A/S
Pfizer Inc.
Eli Lilly and Company
VIVUS LLC
Boehringer Ingelheim International GmbH
AstraZeneca plc
Rhythm Pharmaceuticals Inc
Amgen Inc

第12章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
分析方法
簡稱

簡介目錄

Product Code: KSI061615573

The anti-obesity drug market, sustaining a 19.04% CAGR, is anticipated to reach USD 116.381 billion in 2031 from USD 40.898 billion in 2025.

The anti-obesity drug market is positioned for steady growth, propelled by the escalating global prevalence of obesity and its associated health burdens. These pharmaceutical interventions, which function through mechanisms such as appetite suppression and catecholamine release, offer a medically-supported pathway for weight management and sustainable health. The market's expansion is driven by a confluence of demographic, lifestyle, and regulatory factors that underscore the critical need for effective therapeutic solutions.

A primary market driver is the increasing global prevalence of obesity across all age groups, including a concerning rise in childhood obesity. This widespread health issue creates a substantial and growing patient population in need of medical intervention. The demand for anti-obesity medications is further amplified by the serious adverse health effects strongly correlated with obesity. The condition is a significant risk factor for multiple chronic diseases, including type 2 diabetes and various forms of cancer, positioning it as a major contributor to premature mortality worldwide. This direct link to life-threatening comorbidities underscores the therapeutic necessity of anti-obesity pharmacotherapy.

Modern lifestyle patterns represent another significant contributor to market growth. Factors such as prolonged sedentary behavior, particularly in corporate environments, consumption of processed foods, irregular sleep schedules, and chronic stress have created environmental conditions conducive to obesity. The pervasive integration of digital technology into daily life further compounds these sedentary habits. These collective lifestyle shifts have established a sustained demographic base requiring pharmaceutical support for weight management.

Governmental and institutional initiatives are actively shaping the market landscape. International health organizations and national health departments are implementing awareness campaigns and technical frameworks aimed at combating obesity, particularly focusing on protective measures for children. These public health efforts serve to educate populations about weight-related health risks and legitimize obesity as a condition requiring medical management, thereby fostering a more receptive environment for anti-obesity treatments.

North America emerges as the dominant regional market, a status reinforced by high obesity rates and a progressive regulatory framework. The region benefits from multiple FDA approvals for weight management medications designated for long-term use, providing clinicians with a range of therapeutic options. The presence of major pharmaceutical companies, combined with advanced technological infrastructure and substantial research and development activities, further consolidates North America's leadership position in both adoption and innovation within the anti-obesity drug sector.

The market presents significant opportunities for development, particularly through the creation of advanced therapeutic agents that offer improved efficacy and safety profiles. The substantial global mortality attributed to obesity highlights the urgent need for more effective pharmaceutical interventions. However, market growth is tempered by certain restraining factors, including stringent government regulations governing drug approval and usage. Additional challenges include low utilization rates of weight management services and prescribing limitations that restrict use to specific patient populations based on Body Mass Index and comorbidities.

The competitive landscape features specialized pharmaceutical companies such as Currax Pharmaceuticals and GlaxoSmithKline, which market approved products like Contrave(R) and Alli(R). These players are increasingly focusing on personalized treatment approaches and public awareness campaigns that address the varied physiological and behavioral aspects of obesity, reflecting a maturation in how the condition is understood and treated within the medical community.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Anti-Obesity Drugs Market Segmentation:

By Mechanism of Action
Peripherally Acting Drugs
Centrally Acting Drugs
By Drug Type
Prescription Drugs
OTC Drugs
By Mode of Administration
Oral
Injectable
By End-User
Adults
Children & Youngsters
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. ANTI-OBESITY DRUGS MARKET BY MECHANISM OF ACTION

5.1. Introduction
5.2. Peripherally Acting Drugs
5.3. Centrally Acting Drugs

6. ANTI-OBESITY DRUGS MARKET BY DRUG TYPE

6.1. Introduction
6.2. Prescription Drugs
6.3. OTC Drugs

7. ANTI-OBESITY DRUGS MARKET BY MODE OF ADMINISTRATION

7.1. Introduction
7.2. Oral
7.3. Inectable

8. ANTI-OBESITY DRUGS MARKET BY END-USER

8.1. Introduction
8.2. Adults
8.3. Children & Youngsters

9. ANTI-OBESITY DRUGS MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. By Mechanism of Action
- 9.2.2. By Type
- 9.2.3. By Mode of Administration
- 9.2.4. By End-User
- 9.2.5. By Country
  - 9.2.5.1. USA
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. South America
- 9.3.1. By Mechanism of Action
- 9.3.2. By Type
- 9.3.3. By Mode of Administration
- 9.3.4. By End-User
- 9.3.5. By Country
  - 9.3.5.1. Brazil
  - 9.3.5.2. Argentina
  - 9.3.5.3. Others
9.4. Europe
- 9.4.1. By Mechanism of Action
- 9.4.2. By Type
- 9.4.3. By Mode of Administration
- 9.4.4. By End-User
- 9.4.5. By Country
  - 9.4.5.1. Germany
  - 9.4.5.2. France
  - 9.4.5.3. United Kingdom
  - 9.4.5.4. Spain
  - 9.4.5.5. Others
9.5. Middle East and Africa
- 9.5.1. By Mechanism of Action
- 9.5.2. By Type
- 9.5.3. By Mode of Administration
- 9.5.4. By End-User
- 9.5.5. By Country
  - 9.5.5.1. Saudi Arabia
  - 9.5.5.2. UAE
  - 9.5.5.3. Israel
  - 9.5.5.4. Others
9.6. Asia Pacific
- 9.6.1. By Mechanism of Action
- 9.6.2. By Type
- 9.6.3. By Mode of Administration
- 9.6.4. By End-User
- 9.6.5. By Country
  - 9.6.5.1. China
  - 9.6.5.2. India
  - 9.6.5.3. Japan
  - 9.6.5.4. South Korea
  - 9.6.5.5. Indonesia
  - 9.6.5.6. Thailand
  - 9.6.5.7. Taiwan
  - 9.6.5.8. Others